The treatment of major depressive disorder (MDD) is still a challenge. In the search for novel antidepressants, glutamatergic neuromodulators have been investigated as possible fast-acting antidepressants. Innovative studies suggest that the purine cycle and/or the purinergic signaling can be dysregulated in MDD, and the endogenous nucleoside guanosine has gained attention due to its extracellular effects. This study aimed to verify if guanosine produces fast-onset effects in the wellvalidated, reliable and sensitive olfactory bulbectomy (OBX) model of depression. The involvement of the mTOR pathway, a key target for the fast-onset effect of ketamine, was also investigated. Results show that a single i.p. injection of guanosine, or ketamine, completely reversed the OBX-induced anhedonic-like behavior 24 or 48 h post treatment, as well as the short-term recognition memory impairment 48 h post treatment. The antidepressant-like effects of guanosine and ketamine were completely abolished by rapamycin. This study shows, for the first time, that guanosine, in a way similar to ketamine, is able to elicit a fast antidepressant response in the OBX model in mice. The results support the notion that guanosine represents a new road for therapeutic improvement in MDD. Major depressive disorder (MDD), a severe psychiatric condition, is characterized by high prevalence 1 and disability for affected individuals 2,3 , leading to elevated economic burden 1,4 and a substantial percentage (circa 30%) of patients unresponsive to treatment 4,5. Though this picture vindicates the search for superior medication 6 , unfortunately most research results has been limited to more drugs with the same mechanism of action, or at best certain incremental innovation 7,8. A major flaw in treating depression is the time lag between the onset of the treatment and the remission of the symptoms 4. Especially relevant for treating patients is skepticism, this delay obstructs adhesion, prolongs suffering and disability, and increase suicide risk 4,9. Ketamine has emerged as a fast-acting antidepressant agent that is effective to elicit rapid effect even for severe depressed patients refractory to antidepressant treatment 10. However, ketamine seems to be an unsecure drug especially under repeated administration. This limitation of ketamine's use has lead to renewed efforts for pursuing novel fast-acting antidepressant agents, especially glutamatergic neuromodulators, including guanosine (GUO) 9,11-13. Several lines of evidence suggest that the purine cycle and/or the purinergic signaling could be dysregulated in MDD patients 14-17. As purinergic signaling modulate cell proliferation, differentiation, neuron-glia crosstalk, and inflammation 17-19 , disturbances in purine homeostasis contribute to the pathophysiological process underlying MDD 15,18. GUO is an endogenous nucleoside with neuroprotective effects shown in different animal models of brain disorders 17,20,21. In conditions under which brain homeostasis is disrupted GUO seems to play an importa...